TY - JOUR T1 - Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer’s disease: an observational clinical study JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 1219 LP - 1226 DO - 10.1136/jnnp-2020-323603 VL - 91 IS - 11 AU - Jay Amin AU - Delphine Boche AU - Zoe Clough AU - Jessica Teeling AU - Anthony Williams AU - Yifang Gao AU - Lindsey Chudley AU - Laurie Lau AU - Florence Smith AU - Scott Harris AU - Clive Holmes Y1 - 2020/11/01 UR - http://jnnp.bmj.com/content/91/11/1219.abstract N2 - Background Inflammation plays a key role in the aetiology and progression of Alzheimer’s disease (AD). However, the immunophenotype of the second most common neurodegenerative cause of dementia, dementia with Lewy bodies (DLB), remains unclear. To date there have been no studies examining peripheral inflammation in DLB using multiplex immunoassay and flow cytometry concomitantly. We hypothesised that, using blood biomarkers, DLB would show an increased proinflammatory profile compared with controls, and that there would be a distinct profile compared with AD.Methods 93 participants (31 with DLB, 31 with AD and 31 healthy older controls) completed a single study visit for neuropsychiatric testing and phlebotomy. Peripheral blood mononuclear cells were quantified for T and B cell subsets using flow cytometry, and serum cytokine concentrations were measured using multiplex immunoassay.Results We detected reduced relative numbers of helper T cells and reduced activation of B cells in DLB compared with AD. Additionally, interleukin (IL)-1β was detected more frequently in DLB and the serum concentration of IL-6 was increased compared with controls.Conclusions Peripheral inflammation is altered in DLB compared with AD, with T cell subset analysis supporting a possible shift towards senescence of the adaptive immune system in DLB. Furthermore, there is a proinflammatory signature of serum cytokines in DLB. Identification of this unique peripheral immunophenotype in DLB could guide development of an immune-based biomarker and direct future work exploring potential immune modulation as a novel treatment. ER -